MDT-AP-0810
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 54.72
- os_event
- true
- age_years
- 5.99
- sex
- F
- new_clusters
- C5
- umap1_2d
- 5.815000398
- umap2_2d
- 6.153405416
- umap1_3d
- 3.116088454
- umap2_3d
- -0.093239672
- umap3_3d
- -2.745348764
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.280
- MYOGENESIS+0.180
- PANCREAS_BETA_CELLS+0.110
- APICAL_SURFACE+0.100
- ESTROGEN_RESPONSE_EARLY+0.040
- ESTROGEN_RESPONSE_LATE+0.040
- BILE_ACID_METABOLISM+0.020
- NOTCH_SIGNALING+0.020
- HEDGEHOG_SIGNALING+0.010
- INTERFERON_ALPHA_RESPONSE+0.010
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V1-0.660
- MYC_TARGETS_V2-0.650
- G2M_CHECKPOINT-0.610
- UNFOLDED_PROTEIN_RESPONSE-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- MTORC1_SIGNALING-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
- ANGIOGENESIS-0.350
- DNA_REPAIR-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_G9XE3N9T | pilocytic astrocytoma | — | 0.945 |
| 2 | TCGA-97-A4M1-01A-11R-A24X-07 | — | cohortA1 | 0.902 |
| 3 | BS_ERWT0ZWE | Med | Medulloblastoma | 0.899 |
| 4 | BS_V7BJM89K | low-grade glioma | — | 0.898 |
| 5 | C3N-02950 | — | cohortA1 | 0.889 |
| 6 | BS_063ERW0R | pilocytic astrocytoma | — | 0.888 |
| 7 | BS_SFKZSJN1 | low-grade glioma | — | 0.884 |
| 8 | MNG14 | — | — | 0.881 |
| 9 | MDT-AP-0373 | Med | Medulloblastoma | 0.880 |
| 10 | BS_92VDQ0NE | Ganglioglioma | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.010 | Inavolisib | — uncovered |